RNAseq correlative biomarkers IFIT1B and VSTM5 predict progression free survival and clinical benefit in a multi-site Phase I/II trial of Olaparib and Tremelimumab for gBRCAm recurrent ovarian cancer (LBA 11)

Autor:	Sarah Adams, Carolyn Muller, David O’Malley, Kari Ring, Robert Wenham, Karen Finkelstein, Teresa Rutledge, Elizabeth Lokich, Xavier Paliard, Olivier Rixe, Ichiko Kinjyo, Steven Eberhardt, Ji-Hyun Lee, Phyllis Gimotty
Rok vydání:	2022
Předmět:	Oncology Obstetrics and Gynecology
Zdroj:	Gynecologic Oncology. 166:S60-S61
ISSN:	0090-8258
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fbab2655aa34099daa29b627551a1e7c https://doi.org/10.1016/s0090-8258(22)01315-4 Zobrazit plný text záznamu Full Text from ScienceDirect